Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Beran

Showing results (191-200 of 251) with videos related to

Pageof 26
Sort By:
The American Journal of Medicine|December 1, 1992
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemiaH M Kantarjian, T Smith, E Estey, et al.
Leukemia & Lymphoma|January 1, 1993
Treatment of myelodysplastic syndromes with AML-type chemotherapyE Estey, S Pierce, H Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I studyM Beran, S Jeha, S O'Brien, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1991
Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purgingB Calabretta, R B Sims, M Valtieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemiaS M O'Brien, H M Kantarjian, J Cortes, et al.
Cancer|July 10, 2001
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemiaJ Cortes, E Estey, S O'Brien, et al.
Blood|April 9, 1999
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromeE H Estey, P F Thall, S Pierce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factorE Estey, P Thall, M Andreeff, et al.
Leukemia & Lymphoma|June 1, 1993
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose scheduleA Kemena, S O'Brien, H Kantarjian, et al.
Nature|February 12, 1987
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemiaR Kurzrock, M Shtalrid, P Romero, et al.
Pageof 26

Showing results (191-200 of 251) with videos related to

Sort By:
Pageof 26
The American Journal of Medicine|December 1, 1992
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemiaH M Kantarjian, T Smith, E Estey, et al.
Leukemia & Lymphoma|January 1, 1993
Treatment of myelodysplastic syndromes with AML-type chemotherapyE Estey, S Pierce, H Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I studyM Beran, S Jeha, S O'Brien, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1991
Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purgingB Calabretta, R B Sims, M Valtieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemiaS M O'Brien, H M Kantarjian, J Cortes, et al.
Cancer|July 10, 2001
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemiaJ Cortes, E Estey, S O'Brien, et al.
Blood|April 9, 1999
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromeE H Estey, P F Thall, S Pierce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factorE Estey, P Thall, M Andreeff, et al.
Leukemia & Lymphoma|June 1, 1993
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose scheduleA Kemena, S O'Brien, H Kantarjian, et al.
Nature|February 12, 1987
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemiaR Kurzrock, M Shtalrid, P Romero, et al.
Pageof 26